{"pmid":32377375,"pmcid":"PMC7197635","title":"Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing.","text":["Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing.","COVID-19, caused by SARS-CoV-2, has recently affected over 1,200,000 people and killed more than 60,000. The key immune cell subsets change and their states during the course of COVID-19 remain unclear. We sought to comprehensively characterize the transcriptional changes in peripheral blood mononuclear cells during the recovery stage of COVID-19 by single-cell RNA sequencing technique. It was found that T cells decreased remarkably, whereas monocytes increased in patients in the early recovery stage (ERS) of COVID-19. There was an increased ratio of classical CD14(++) monocytes with high inflammatory gene expression as well as a greater abundance of CD14(++)IL1beta(+) monocytes in the ERS. CD4(+) T cells and CD8(+) T cells decreased significantly and expressed high levels of inflammatory genes in the ERS. Among the B cells, the plasma cells increased remarkably, whereas the naive B cells decreased. Several novel B cell-receptor (BCR) changes were identified, such as IGHV3-23 and IGHV3-7, and isotypes (IGHV3-15, IGHV3-30, and IGKV3-11) previously used for virus vaccine development were confirmed. The strongest pairing frequencies, IGHV3-23-IGHJ4, indicated a monoclonal state associated with SARS-CoV-2 specificity, which had not been reported yet. Furthermore, integrated analysis predicted that IL-1beta and M-CSF may be novel candidate target genes for inflammatory storm and that TNFSF13, IL-18, IL-2, and IL-4 may be beneficial for the recovery of COVID-19 patients. Our study provides the first evidence of an inflammatory immune signature in the ERS, suggesting COVID-19 patients are still vulnerable after hospital discharge. Identification of novel BCR signaling may lead to the development of vaccines and antibodies for the treatment of COVID-19.","Cell Discov","Wen, Wen","Su, Wenru","Tang, Hao","Le, Wenqing","Zhang, Xiaopeng","Zheng, Yingfeng","Liu, Xiuxing","Xie, Lihui","Li, Jianmin","Ye, Jinguo","Dong, Liwei","Cui, Xiuliang","Miao, Yushan","Wang, Depeng","Dong, Jiantao","Xiao, Chuanle","Chen, Wei","Wang, Hongyang","32377375"],"abstract":["COVID-19, caused by SARS-CoV-2, has recently affected over 1,200,000 people and killed more than 60,000. The key immune cell subsets change and their states during the course of COVID-19 remain unclear. We sought to comprehensively characterize the transcriptional changes in peripheral blood mononuclear cells during the recovery stage of COVID-19 by single-cell RNA sequencing technique. It was found that T cells decreased remarkably, whereas monocytes increased in patients in the early recovery stage (ERS) of COVID-19. There was an increased ratio of classical CD14(++) monocytes with high inflammatory gene expression as well as a greater abundance of CD14(++)IL1beta(+) monocytes in the ERS. CD4(+) T cells and CD8(+) T cells decreased significantly and expressed high levels of inflammatory genes in the ERS. Among the B cells, the plasma cells increased remarkably, whereas the naive B cells decreased. Several novel B cell-receptor (BCR) changes were identified, such as IGHV3-23 and IGHV3-7, and isotypes (IGHV3-15, IGHV3-30, and IGKV3-11) previously used for virus vaccine development were confirmed. The strongest pairing frequencies, IGHV3-23-IGHJ4, indicated a monoclonal state associated with SARS-CoV-2 specificity, which had not been reported yet. Furthermore, integrated analysis predicted that IL-1beta and M-CSF may be novel candidate target genes for inflammatory storm and that TNFSF13, IL-18, IL-2, and IL-4 may be beneficial for the recovery of COVID-19 patients. Our study provides the first evidence of an inflammatory immune signature in the ERS, suggesting COVID-19 patients are still vulnerable after hospital discharge. Identification of novel BCR signaling may lead to the development of vaccines and antibodies for the treatment of COVID-19."],"journal":"Cell Discov","authors":["Wen, Wen","Su, Wenru","Tang, Hao","Le, Wenqing","Zhang, Xiaopeng","Zheng, Yingfeng","Liu, Xiuxing","Xie, Lihui","Li, Jianmin","Ye, Jinguo","Dong, Liwei","Cui, Xiuliang","Miao, Yushan","Wang, Depeng","Dong, Jiantao","Xiao, Chuanle","Chen, Wei","Wang, Hongyang"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32377375","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1038/s41421-020-0168-9","keywords":["immunology","mechanisms of disease"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666262687602966528,"score":9.490897,"similar":[{"pmid":32398875,"title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19.","text":["Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19.","Respiratory immune characteristics associated with Coronavirus Disease 2019 (COVID-19) severity are currently unclear. We characterized bronchoalveolar lavage fluid immune cells from patients with varying severity of COVID-19 and from healthy people by using single-cell RNA sequencing. Proinflammatory monocyte-derived macrophages were abundant in the bronchoalveolar lavage fluid from patients with severe COVID-9. Moderate cases were characterized by the presence of highly clonally expanded CD8(+) T cells. This atlas of the bronchoalveolar immune microenvironment suggests potential mechanisms underlying pathogenesis and recovery in COVID-19.","Nat Med","Liao, Mingfeng","Liu, Yang","Yuan, Jing","Wen, Yanling","Xu, Gang","Zhao, Juanjuan","Cheng, Lin","Li, Jinxiu","Wang, Xin","Wang, Fuxiang","Liu, Lei","Amit, Ido","Zhang, Shuye","Zhang, Zheng","32398875"],"abstract":["Respiratory immune characteristics associated with Coronavirus Disease 2019 (COVID-19) severity are currently unclear. We characterized bronchoalveolar lavage fluid immune cells from patients with varying severity of COVID-19 and from healthy people by using single-cell RNA sequencing. Proinflammatory monocyte-derived macrophages were abundant in the bronchoalveolar lavage fluid from patients with severe COVID-9. Moderate cases were characterized by the presence of highly clonally expanded CD8(+) T cells. This atlas of the bronchoalveolar immune microenvironment suggests potential mechanisms underlying pathogenesis and recovery in COVID-19."],"journal":"Nat Med","authors":["Liao, Mingfeng","Liu, Yang","Yuan, Jing","Wen, Yanling","Xu, Gang","Zhao, Juanjuan","Cheng, Lin","Li, Jinxiu","Wang, Xin","Wang, Fuxiang","Liu, Lei","Amit, Ido","Zhang, Shuye","Zhang, Zheng"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32398875","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1038/s41591-020-0901-9","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666714494788698112,"score":353.37915},{"pmid":32399213,"pmcid":"PMC7211507","title":"Dynamics of peripheral immune cells and their HLA-G and receptor expressions in a patient suffering from critical COVID-19 pneumonia to convalescence.","text":["Dynamics of peripheral immune cells and their HLA-G and receptor expressions in a patient suffering from critical COVID-19 pneumonia to convalescence.","Objectives: Host immune responses are indispensable to combat the disease. We report the dynamics of peripheral immune cells, cytokines, and human leucocyte antigen-G (HLA-G) and its receptor expressions in a patient suffering from critical COVID-19 pneumonia to convalescence. Methods: Clinical data of the patient were collected from medical records. The expressions of HLA-G and receptors ILT2, ILT4 and KIR2DL4 in peripheral immune cells were measured with flow cytometry. Results: From critical COVID-19 to the convalescent stage, early lymphopenia was improved (median: 0.6 x 10(9) L(-1) vs. 0.9 x 10(9) L(-1), P = 0.009), and an obvious fluctuation in WBC and neutrophil counts was observed. Initially, low levels of CD4(+) T cells (from 120 to 528 muL(-1)) and CD8(+) T cells (from 68 to 362 muL(-1)) gradually increased to normal levels. Meanwhile, high IL-6 (from 251.8 to 6.32 pg mL(-1)), IL-10 (from 39.53 to 5.21 pg mL(-1)) and IFN-gamma (from 13.55 to 3.16 pg mL(-1)) levels decreased, and IL-4 (from 2.36 to 3.19 pg mL(-1)) and TNF-alpha (from 2.27 to 20.2 pg mL(-1)) levels increased quickly when the viral RNA returned negative. Moreover, the percentage of HLA-G(+) T cells, B cells and monocytes follows high-low-high pattern, while the percentage of receptors ILT2-, ILT4- and KIR2DL4-expressing cells remained relatively stable. Conclusion: Our findings provide valuable information on the dynamics of early peripheral immunological responses in SARS-CoV-2 infection. CD4(+) and CD8(+) T cells, cytokines and HLA-G(+) immune cells are associated with the natural history of the critical COVID-19 patient; however, future studies are necessary.","Clin Transl Immunology","Zhang, Sheng","Gan, Jun","Chen, Bao-Guo","Zheng, Dan","Zhang, Jian-Gang","Lin, Rong-Hai","Zhou, Yi-Ping","Yang, Wei-Ying","Lin, Aifen","Yan, Wei-Hua","32399213"],"abstract":["Objectives: Host immune responses are indispensable to combat the disease. We report the dynamics of peripheral immune cells, cytokines, and human leucocyte antigen-G (HLA-G) and its receptor expressions in a patient suffering from critical COVID-19 pneumonia to convalescence. Methods: Clinical data of the patient were collected from medical records. The expressions of HLA-G and receptors ILT2, ILT4 and KIR2DL4 in peripheral immune cells were measured with flow cytometry. Results: From critical COVID-19 to the convalescent stage, early lymphopenia was improved (median: 0.6 x 10(9) L(-1) vs. 0.9 x 10(9) L(-1), P = 0.009), and an obvious fluctuation in WBC and neutrophil counts was observed. Initially, low levels of CD4(+) T cells (from 120 to 528 muL(-1)) and CD8(+) T cells (from 68 to 362 muL(-1)) gradually increased to normal levels. Meanwhile, high IL-6 (from 251.8 to 6.32 pg mL(-1)), IL-10 (from 39.53 to 5.21 pg mL(-1)) and IFN-gamma (from 13.55 to 3.16 pg mL(-1)) levels decreased, and IL-4 (from 2.36 to 3.19 pg mL(-1)) and TNF-alpha (from 2.27 to 20.2 pg mL(-1)) levels increased quickly when the viral RNA returned negative. Moreover, the percentage of HLA-G(+) T cells, B cells and monocytes follows high-low-high pattern, while the percentage of receptors ILT2-, ILT4- and KIR2DL4-expressing cells remained relatively stable. Conclusion: Our findings provide valuable information on the dynamics of early peripheral immunological responses in SARS-CoV-2 infection. CD4(+) and CD8(+) T cells, cytokines and HLA-G(+) immune cells are associated with the natural history of the critical COVID-19 patient; however, future studies are necessary."],"journal":"Clin Transl Immunology","authors":["Zhang, Sheng","Gan, Jun","Chen, Bao-Guo","Zheng, Dan","Zhang, Jian-Gang","Lin, Rong-Hai","Zhou, Yi-Ping","Yang, Wei-Ying","Lin, Aifen","Yan, Wei-Hua"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32399213","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1002/cti2.1128","keywords":["covid-19","hla-g","sars-cov-2","peripheral immune cells"],"locations":["neutrophil"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666714494970101760,"score":326.29712},{"pmid":32257537,"pmcid":"PMC7069465","title":"Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.","text":["Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.","A coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China. Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improves the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China, from Jan 23, 2020 to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs could cure or significantly improve the functional outcomes of seven patients without observed adverse effects. The pulmonary function and symptoms of these seven patients were significantly improved in 2 days after MSC transplantation. Among them, two common and one severe patient were recovered and discharged in 10 days after treatment. After treatment, the peripheral lymphocytes were increased, the C-reactive protein decreased, and the overactivated cytokine-secreting immune cells CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells disappeared in 3-6 days. In addition, a group of CD14+CD11c+CD11b(mid) regulatory DC cell population dramatically increased. Meanwhile, the level of TNF-alpha was significantly decreased, while IL-10 increased in MSC treatment group compared to the placebo control group. Furthermore, the gene expression profile showed MSCs were ACE2(-) and TMPRSS2(-) which indicated MSCs are free from COVID-19 infection. Thus, the intravenous transplantation of MSCs was safe and effective for treatment in patients with COVID-19 pneumonia, especially for the patients in critically severe condition.","Aging Dis","Leng, Zikuan","Zhu, Rongjia","Hou, Wei","Feng, Yingmei","Yang, Yanlei","Han, Qin","Shan, Guangliang","Meng, Fanyan","Du, Dongshu","Wang, Shihua","Fan, Junfen","Wang, Wenjing","Deng, Luchan","Shi, Hongbo","Li, Hongjun","Hu, Zhongjie","Zhang, Fengchun","Gao, Jinming","Liu, Hongjian","Li, Xiaoxia","Zhao, Yangyang","Yin, Kan","He, Xijing","Gao, Zhengchao","Wang, Yibin","Yang, Bo","Jin, Ronghua","Stambler, Ilia","Lim, Lee Wei","Su, Huanxing","Moskalev, Alexey","Cano, Antonio","Chakrabarti, Sasanka","Min, Kyung-Jin","Ellison-Hughes, Georgina","Caruso, Calogero","Jin, Kunlin","Zhao, Robert Chunhua","32257537"],"abstract":["A coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China. Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improves the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China, from Jan 23, 2020 to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs could cure or significantly improve the functional outcomes of seven patients without observed adverse effects. The pulmonary function and symptoms of these seven patients were significantly improved in 2 days after MSC transplantation. Among them, two common and one severe patient were recovered and discharged in 10 days after treatment. After treatment, the peripheral lymphocytes were increased, the C-reactive protein decreased, and the overactivated cytokine-secreting immune cells CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells disappeared in 3-6 days. In addition, a group of CD14+CD11c+CD11b(mid) regulatory DC cell population dramatically increased. Meanwhile, the level of TNF-alpha was significantly decreased, while IL-10 increased in MSC treatment group compared to the placebo control group. Furthermore, the gene expression profile showed MSCs were ACE2(-) and TMPRSS2(-) which indicated MSCs are free from COVID-19 infection. Thus, the intravenous transplantation of MSCs was safe and effective for treatment in patients with COVID-19 pneumonia, especially for the patients in critically severe condition."],"journal":"Aging Dis","authors":["Leng, Zikuan","Zhu, Rongjia","Hou, Wei","Feng, Yingmei","Yang, Yanlei","Han, Qin","Shan, Guangliang","Meng, Fanyan","Du, Dongshu","Wang, Shihua","Fan, Junfen","Wang, Wenjing","Deng, Luchan","Shi, Hongbo","Li, Hongjun","Hu, Zhongjie","Zhang, Fengchun","Gao, Jinming","Liu, Hongjian","Li, Xiaoxia","Zhao, Yangyang","Yin, Kan","He, Xijing","Gao, Zhengchao","Wang, Yibin","Yang, Bo","Jin, Ronghua","Stambler, Ilia","Lim, Lee Wei","Su, Huanxing","Moskalev, Alexey","Cano, Antonio","Chakrabarti, Sasanka","Min, Kyung-Jin","Ellison-Hughes, Georgina","Caruso, Calogero","Jin, Kunlin","Zhao, Robert Chunhua"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32257537","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.14336/AD.2020.0228","keywords":["ace2 negative","covid-19","cell transplantation","function recovery","immunomodulation","mesenchymal stem cells"],"locations":["Wuhan","China","China","Pneumonia"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138493139550210,"score":309.63605},{"pmid":32502135,"title":"Reduced monocytic HLA-DR expression indicates immunosuppression in critically ill COVID-19 patients.","text":["Reduced monocytic HLA-DR expression indicates immunosuppression in critically ill COVID-19 patients.","BACKGROUND: The cellular immune system is of pivotal importance with regard to the response to severe infections. Monocytes / macrophages are considered key immune cells in infections and downregulation of the surface expression of monocytic human leukocyte antigen-DR (mHLA-DR) expression within the major histocompatibility complex class II reflects a state of immunosuppression, also referred to as injury-associated immunosuppression. As the role of immunosuppression in coronavirus disease 2019 (COVID-19) disease is currently unclear, we seek to explore the level of mHLA-DR expression in COVID-19 patients. METHODS: In a preliminary prospective monocentric observational study, 16 COVID-19 positive patients (75% male, median age: 68 [interquartile range 59-75], APACHE-II score in 9 ICU patients: 30 [interquartile range 25-32] with acute respiratory failure were included. Standardized quantitative assessment of mHLA-DR on CD14+ cells was performed using calibrated flow cytometry at baseline (ICU admission), and at days 3 and 5 after ICU admission. Baseline data was compared to hospitalized non-critically ill COVID-19 patients. RESULTS: While normal mHLA-DR expression was observed in all hospitalized non-critically ill patients (n=7), 89% (8/9) critically ill patients with COVID-19- induced acute respiratory failure showed signs of downregulation of mHLA-DR at ICU admission. Monocytic HLA-DR expression at admission was significantly lower in critically ill patients (median, [quartiles]: 9280 antibodies/cell [6114, 16567]) as compared to the non-critically ill patients (30900 antibodies/cell [26777, 52251]), with a median difference of 21508 antibodies/cell (95% CI: 14118 to 42971), P=0.002. Reduced monocytic HLA-DR expression was observed to persist until day 5 after ICU admission. CONCLUSIONS: When compared to non-critically ill hospitalized COVID-19 patients, ICU patients with severe COVID-19 disease showed reduced mHLA-DR expression on circulating CD14+ monocytes at ICU admission, indicating a dysfunctional immune response. This immunosuppressive (monocytic) phenotype remained unchanged over the ensuing days after ICU admission. Strategies aiming for immunomodulation in this population of critically ill patients should be guided by an immune-monitoring program in an effort to determine who might benefit best from a given immunological intervention.","Anesth Analg","Spinetti, Thibaud","Hirzel, Cedric","Fux, Michaela","Walti, Laura N","Schober, Patrick","Stueber, Frank","Luedi, Markus M","Schefold, Joerg C","32502135"],"abstract":["BACKGROUND: The cellular immune system is of pivotal importance with regard to the response to severe infections. Monocytes / macrophages are considered key immune cells in infections and downregulation of the surface expression of monocytic human leukocyte antigen-DR (mHLA-DR) expression within the major histocompatibility complex class II reflects a state of immunosuppression, also referred to as injury-associated immunosuppression. As the role of immunosuppression in coronavirus disease 2019 (COVID-19) disease is currently unclear, we seek to explore the level of mHLA-DR expression in COVID-19 patients. METHODS: In a preliminary prospective monocentric observational study, 16 COVID-19 positive patients (75% male, median age: 68 [interquartile range 59-75], APACHE-II score in 9 ICU patients: 30 [interquartile range 25-32] with acute respiratory failure were included. Standardized quantitative assessment of mHLA-DR on CD14+ cells was performed using calibrated flow cytometry at baseline (ICU admission), and at days 3 and 5 after ICU admission. Baseline data was compared to hospitalized non-critically ill COVID-19 patients. RESULTS: While normal mHLA-DR expression was observed in all hospitalized non-critically ill patients (n=7), 89% (8/9) critically ill patients with COVID-19- induced acute respiratory failure showed signs of downregulation of mHLA-DR at ICU admission. Monocytic HLA-DR expression at admission was significantly lower in critically ill patients (median, [quartiles]: 9280 antibodies/cell [6114, 16567]) as compared to the non-critically ill patients (30900 antibodies/cell [26777, 52251]), with a median difference of 21508 antibodies/cell (95% CI: 14118 to 42971), P=0.002. Reduced monocytic HLA-DR expression was observed to persist until day 5 after ICU admission. CONCLUSIONS: When compared to non-critically ill hospitalized COVID-19 patients, ICU patients with severe COVID-19 disease showed reduced mHLA-DR expression on circulating CD14+ monocytes at ICU admission, indicating a dysfunctional immune response. This immunosuppressive (monocytic) phenotype remained unchanged over the ensuing days after ICU admission. Strategies aiming for immunomodulation in this population of critically ill patients should be guided by an immune-monitoring program in an effort to determine who might benefit best from a given immunological intervention."],"journal":"Anesth Analg","authors":["Spinetti, Thibaud","Hirzel, Cedric","Fux, Michaela","Walti, Laura N","Schober, Patrick","Stueber, Frank","Luedi, Markus M","Schefold, Joerg C"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32502135","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1213/ANE.0000000000005044","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668804508878110720,"score":293.24377},{"pmid":32463803,"title":"Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.","text":["Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.","BACKGROUND: Coronavirus disease 19 (COVID-19) is an emerging infectious disease caused by SARS-CoV-2. Anti-viral immune response is crucial to achieve pathogen clearance, however in some patients an excessive and aberrant host immune response can lead to an acute respiratory distress syndrome. The comprehension of the mechanisms that regulate pathogen elimination, immunity, and pathology is essential to better characterize disease progression and widen the spectrum of therapeutic options. METHODS: We performed a flow cytometric characterization of immune cells subsets from 30 COVID-19 patients and correlated these data with clinical outcomes. RESULTS: COVID-19 patients showed decreased numbers of circulating T, B and NK cells, and exhibited a skewing of CD8+ T cells towards a terminally differentiated/senescent phenotype. In agreement, T CD4+, T CD8+ but also NK cells displayed reduced anti-viral cytokine production capability. Moreover, a reduced cytotoxic potential was identified in COVID-19 patients, particularly in those that required intensive care. The latter group of patients showed also increased serum IL-6 levels, that correlated to the frequency of granzyme-expressing NK cells. Off-label treatment with tocilizumab restored the cytotoxic potential of NK cells. CONCLUSION: In conclusion, the association between IL-6 serum levels and the impairment of cytotoxic activity suggests the possibility that targeting this cytokine may restore anti-viral mechanisms. FUNDING: This study was supported by funds of Dept. of Experimental and Clinical Medicine of University of Florence (ex-60%) derived from Ministero dell'Istruzione, dell'Universita e della Ricerca (Italy).","J Clin Invest","Mazzoni, Alessio","Salvati, Lorenzo","Maggi, Laura","Capone, Manuela","Vanni, Anna","Spinicci, Michele","Mencarini, Jessica","Caporale, Roberto","Peruzzi, Benedetta","Antonelli, Alberto","Trotta, Michele","Zammarchi, Lorenzo","Ciani, Luca","Gori, Leonardo","Lazzeri, Chiara","Matucci, Andrea","Vultaggio, Alessandra","Rossi, Oliviero","Almerigogna, Fabio","Parronchi, Paola","Fontanari, Paolo","Lavorini, Federico","Peris, Adriano","Rossolini, Gian Maria","Bartoloni, Alessandro","Romagnani, Sergio","Liotta, Francesco","Annunziato, Francesco","Cosmi, Lorenzo","32463803"],"abstract":["BACKGROUND: Coronavirus disease 19 (COVID-19) is an emerging infectious disease caused by SARS-CoV-2. Anti-viral immune response is crucial to achieve pathogen clearance, however in some patients an excessive and aberrant host immune response can lead to an acute respiratory distress syndrome. The comprehension of the mechanisms that regulate pathogen elimination, immunity, and pathology is essential to better characterize disease progression and widen the spectrum of therapeutic options. METHODS: We performed a flow cytometric characterization of immune cells subsets from 30 COVID-19 patients and correlated these data with clinical outcomes. RESULTS: COVID-19 patients showed decreased numbers of circulating T, B and NK cells, and exhibited a skewing of CD8+ T cells towards a terminally differentiated/senescent phenotype. In agreement, T CD4+, T CD8+ but also NK cells displayed reduced anti-viral cytokine production capability. Moreover, a reduced cytotoxic potential was identified in COVID-19 patients, particularly in those that required intensive care. The latter group of patients showed also increased serum IL-6 levels, that correlated to the frequency of granzyme-expressing NK cells. Off-label treatment with tocilizumab restored the cytotoxic potential of NK cells. CONCLUSION: In conclusion, the association between IL-6 serum levels and the impairment of cytotoxic activity suggests the possibility that targeting this cytokine may restore anti-viral mechanisms. FUNDING: This study was supported by funds of Dept. of Experimental and Clinical Medicine of University of Florence (ex-60%) derived from Ministero dell'Istruzione, dell'Universita e della Ricerca (Italy)."],"journal":"J Clin Invest","authors":["Mazzoni, Alessio","Salvati, Lorenzo","Maggi, Laura","Capone, Manuela","Vanni, Anna","Spinicci, Michele","Mencarini, Jessica","Caporale, Roberto","Peruzzi, Benedetta","Antonelli, Alberto","Trotta, Michele","Zammarchi, Lorenzo","Ciani, Luca","Gori, Leonardo","Lazzeri, Chiara","Matucci, Andrea","Vultaggio, Alessandra","Rossi, Oliviero","Almerigogna, Fabio","Parronchi, Paola","Fontanari, Paolo","Lavorini, Federico","Peris, Adriano","Rossolini, Gian Maria","Bartoloni, Alessandro","Romagnani, Sergio","Liotta, Francesco","Annunziato, Francesco","Cosmi, Lorenzo"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32463803","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1172/JCI138554","keywords":["cellular immune response","cytokines","immunology","infectious disease","nk cells"],"locations":["Dept. of"],"countries":["Turkey"],"countries_codes":["TUR|Turkey"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521480310785,"score":271.6092}]}